The development of androgen-independent prostate cancer
Top Cited Papers
- 1 October 2001
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 1 (1) , 34-45
- https://doi.org/10.1038/35094009
Abstract
The normal prostate and early-stage prostate cancers depend on androgens for growth and survival, and androgen ablation therapy causes them to regress. Cancers that are not cured by surgery eventually become androgen independent, rendering anti-androgen therapy ineffective. But how does androgen independence arise? We predict that understanding the pathways that lead to the development of androgen-independent prostate cancer will pave the way to effective therapies for these, at present, untreatable cancers.Keywords
This publication has 67 references indexed in Scilit:
- Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences*The Prostate, 2001
- Hormone Status Selects for Spontaneous Somatic Androgen Receptor Variants That Demonstrate Specific Ligand and Cofactor Dependent Activities in Autochthonous Prostate CancerJournal of Biological Chemistry, 2001
- LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasisThe Prostate, 2000
- PTEN: a tumour suppressor that functions as a phospholipid phosphataseTrends in Cell Biology, 1999
- Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTENCell, 1998
- AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian CancerScience, 1997
- PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate CancerScience, 1997
- Androgen receptor gene amplification: A novel molecular mechanism for endocrine therapy resistance in human prostate cancerScandinavian Journal of Clinical and Laboratory Investigation, 1996
- Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate CancerNew England Journal of Medicine, 1995
- The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogensThe Journal of Steroid Biochemistry and Molecular Biology, 1992